Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment

Symeonidis, Argiris; Germing, Ulrich

doi:10.3389/fonc.2023.1166163

Front. Oncol.

2023

DOI: 10.3389/fonc.2023.1166163

|View full text |Cite

Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment

Argiris Symeonidis

Ulrich Germing²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

How we diagnose Myelodysplastic syndromes

Oster,

Mittelman

2024

Front. Oncol.

View full text Add to dashboard Cite

The Myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by ineffective hematopoiesis that results in dysplasia in hematopoietic cells and peripheral cytopenias, especially anemia, and a propensity to leukemic transformation. The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings, but the gold standard for MDS diagnosis is still BM examination with the presence of uni-or multi-lineage dysplasia and increased blast percentage, together with exclusion of other reasons. Cytogenetics is also an essential part of the diagnostic and prognostic processes. Flow cytometry and full genetic characterization are helpful but not mandatory for MDS diagnosis. This review summarizes the current steps of diagnostic approach for a patient suspected of having MDS. We also express our hopes that within the near future, non-invasive technologies, especially digital and peripheral blood genetics, will mature and be introduced into practice.

show abstract

How we diagnose Myelodysplastic syndromes

Oster,

Mittelman

2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment

Cited by 1 publication

References 5 publications

How we diagnose Myelodysplastic syndromes

How we diagnose Myelodysplastic syndromes

Contact Info

Product

Resources

About